Virpax Pharmaceuticals, Inc. VRPX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
21/100
Weak

Ranked against 712 peers in Biotechnology

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based … Full VRPX analysis →

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.31), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.08), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where VRPX ranks in Biotechnology

Virpax Pharmaceuticals, Inc. ranks #602 of 713 scored companies in Biotechnology by moat score — the top 84%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
598 HCW Biologics Inc. HCWB 21/100 Weak
599 Mustang Bio, Inc. MBIO 21/100 Weak
600 Allarity Therapeutics, Inc. ALLR 21/100 Weak
601 Lyell Immunopharma, Inc. LYEL 21/100 Weak
602 Virpax Pharmaceuticals, Inc. VRPX 21/100 Weak
603 OnKure Therapeutics, Inc. OKUR 21/100 Weak
604 Tempest Therapeutics, Inc. TPST 20/100 Weak
605 Hepion Pharmaceuticals, Inc. HEPA 20/100 Weak
606 Connect Biopharma Holdings Limi CNTB 20/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How VRPX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 20 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 22 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding VRPX's moat

What is Virpax Pharmaceuticals, Inc.'s moat score?

Virpax Pharmaceuticals, Inc. (VRPX) scores 21 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #602 of 713 scored companies in Biotechnology, the top 84%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (22/100) and its weakest is Capital Efficiency (20/100).

How does Virpax Pharmaceuticals, Inc. compare with other Biotechnology companies?

Virpax Pharmaceuticals, Inc. ranks #602 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Lyell Immunopharma, Inc. (LYEL) at 21 just above it and OnKure Therapeutics, Inc. (OKUR) at 20 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Virpax Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Virpax Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and VRPX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (20), Resilience (22), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000